Tumor and Non-Tumor Liver Angiogenesis Is Traced and Evaluated by Hepatic Arterial Ultrasound in Murine Models

Ultrasound in Medicine and Biology

Volumn 38, Issue 7, 2012, Pages 1195-1204

  Eveno, Clarisse ^a   Le Henaff, Carole ^b   Audollent, Raphaëlle ^a   Soyer, Philippe ^a   Rampanou, Aurore ^a   Nemeth, Judith ^a   Brouland, Jean Philippe ^a   Dupuy, Evelyne ^a   Pocard, Marc ^a   Bonnin, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Angiogenesis; Liver; Liver regeneration; Metastasis; Mice; Ultrasonography

Indexed keywords

ANGIOGENESIS; ANTIANGIOGENIC; DOPPLER ULTRASONOGRAPHY; FUNCTIONAL EVALUATION; HEPATIC REGENERATION; HUMAN COLON; LIVER METASTASIS; LIVER REGENERATION; LIVER VOLUME; METASTASIS; MICE; MURINE MODEL; TUMOR ANGIOGENESIS; ULTRASOUND IMAGING;

LIVER; MAMMALS; NEONATAL MONITORING; PATHOLOGY; ULTRASONOGRAPHY;

TUMORS;

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN CELL; LIVER BLOOD FLOW; LIVER FUNCTION; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; LIVER TUMOR; LIVER WEIGHT; MESENTERY BLOOD FLOW; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ANGIOGENESIS; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84861900932     PISSN: 03015629     EISSN: 1879291X     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2012.03.004     Document Type: Article

References (51)

1. Adam R., Laurent A., Azoulay D., Castaing D., Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000, 232:777-785.
2. Aussilhou B., Dokmak S., Faivre S., Paradis V., Vilgrain V., Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009, 16:1553-1559.
3. Baker M.E., Pelley R. Hepatic metastases: Basic principles and implications for radiologists. Radiology 1995, 197:329-337.
4. Bonnin P., Villemain A., Vincent F., Debbabi H., Silvestre J.S., Contreres J.O., Levy B.I., Tobelem G., Dupuy E. Ultrasonic assessment of hepatic blood flow as a marker of mouse hepatocarcinoma. Ultrasound Med Biol 2007, 33:561-570.
5. Precision of test method (BS5497, part 1) 1979, British Standards Institution, BSI, London.
6. Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., Chen L.L., Podoloff D.A., Benjamin R.S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
7. Chun Y.S., Vauthey J.N., Boonsirikamchai P., Maru D.M., Kopetz S., Palavecino M., Curley S.A., Abdalla E.K., Kaur H., Charnsangavej C., Loyer E.M. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009, 302:2338-2344.
8. Cianchi F., Palomba A., Messerini L., Boddi V., Asirelli G., Perigli G., Bechi P., Taddei A., Pucciani F., Cortesini C. Tumor angiogenesis in lymph node-negative rectal cancer: Correlation with clinicopathological parameters and prognosis. Ann Surg Oncol 2002, 9:20-26.
9. Covey A.M., Brown K.T., Jarnagin W.R., Brody L.A., Schwartz L., Tuorto S., Sofocleous C.T., D'Angelica M., Getrajdman G.I., DeMatteo R., Kemeny N.E., Fong Y. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008, 247:451-455.
10. Cuenod C., Leconte I., Siauve N., Resten A., Dromain C., Poulet B., Frouin F., Clement O., Frija G. Early changes in liver perfusion caused by occult metastases in rats: Detection with quantitative CT. Radiology 2001, 218:556-561.
11. Ding B.S., Nolan D.J., Butler J.M., James D., Babazadeh A.O., Rosenwaks Z., Mittal V., Kobayashi H., Shido K., Lyden D., Sato T.N., Rabbany S.Y., Rafii S. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010, 468:310-315.
12. Drixler T.A., Vogten M.J., Ritchie E.D., van Vroonhoven T.J., Gebbink M.F., Voest E.E., Borel Rinkes I.H. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 2002, 236:703-711. discussion 11-12.
13. Dupuy E., Hainaud P., Villemain A., Bodevin-Phèdre E., Brouland J.P., Briand P., Tobelem G. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol 2003, 38:793-802.
14. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
15. Elias D., Ouellet J.F., De Baere T., Lasser P., Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastases: Long-term results and impact on survival. Surgery 2002, 131:294-299.
16. Eveno C., Broqueres-You D., Feron J.G., Rampanou A., Tijeras-Raballand A., Ropert S., Leconte L., Levy B.I., Pocard M. Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis. Am J Pathol 2011, 178:1861-1869.
17. Eveno C., Gaujoux S., Tobelem G., Pocard M. Did animal offer relevant model for Bevacizumab testing?. Br J Cancer 2008, 99:1555. author reply 56.
18. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285:1182-1186.
19. Fong Y., Cohen A.M., Fortner J.G., Enker W.E., Turnbull A.D., Coit D.G., Marrero A.M., Prasad M., Blumgart L.H., Brennan M.F. Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
20. Fortner J.G., Silva J.S., Golbey R.B., Cox E.B., Maclean B.J. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984, 199:306-316.
21. Freitas C., Larrivee B., Eichmann A. Netrins and UNC5 receptors in angiogenesis. Angiogenesis 2008, 11:23-29.
22. Grothey A., Hedrick E.E., Mass R.D., Sarkar S., Suzuki S., Ramanathan R.K., Hurwitz H.I., Goldberg R.M., Sargent D.J. Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol 2008, 26:183-189.
23. Hainaud P., Contrerès J.O., Villemain A., Liu L.X., Plouët J., Tobelem G., Dupuy E. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006, 66:8501-8510.
24. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
25. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
26. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
27. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
28. Klinger M., Eipeldauer S., Hacker S., Herberger B., Tamandl D., Dorfmeister M., Koelblinger C., Gruenberger B., Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009, 35:515-520.
29. Kruskal J.B., Thomas P., Kane R.A., Goldberg S.N. Hepatic perfusion changes in mice livers with developing colorectal cancer metastases. Radiology 2004, 231:482-490.
30. Kruskal J.B., Thomas P., Nasser I., Cay O., Kane R.A. Hepatic colon cancer metastases in mice: Dynamic in vivo correlation with hypoechoic rims visible at US. Radiology 2000, 215:852-857.
31. Lassau N., Lamuraglia M., Chami L., Leclere J., Bonvalot S., Terrier P., Roche A., Le Cesne A. Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography. AJR. Am J Roentgenol 2006, 187:1267-1273.
32. Leen E., Goldberg J.A., Angerson W.J., McArdle C.S. Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. Lancet 2000, 355:34-37.
33. Leggett D.A., Kelley B.B., Bunce I.H., Miles K.A. Colorectal cancer: Diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 1997, 205:716-720.
34. Lejmi E., Leconte L., Pedron-Mazoyer S., Ropert S., Raoul W., Lavalette S., Bouras I., Feron J.G., Maitre-Boube M., Assayag F., Feumi C., Alemany M., Jie T.X., Merkulova T., Poupon M.F., Ruchoux M.M., Tobelem G., Sennlaub F., Plouet J. Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proc Natl Acad Sci USA 2008, 105:12491-12496.
35. Leonard G.D., Brenner B., Kemeny N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005, 23:2038-2048.
36. Liu Y., Matsui O. Changes of intratumoral microvessels and blood perfusion during establishment of hepatic metastases in mice. Radiology 2007, 243:386-395.
37. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116:2610-2621.
38. Nanashima A., Ito M., Sekine I., Naito S., Yamaguchi H., Nakagoe T., Ayabe H. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 1998, 43:2634-2640.
39. Platt J.F., Francis I.R., Ellis J.H., Reige K.A. Liver metastases: Early detection based on abnormal contrast material enhancement at dual-phase helical CT. Radiology 1997, 205:49-53.
40. Rajaganeshan R., Prasad R., Guillou P.J., Chalmers C.R., Scott N., Sarkar R., Poston G., Jayne D.G. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Can 2007, 96:1112-1117.
41. Ratain M.J., Eckhardt S.G. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 2004, 22:4442-4445.
42. Scheele J., Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbeck Arch Surg 1999, 384:313-327.
43. Scheele J., Stang R., Altendorf-Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg 1995, 19:59-71.
44. Stangl R., Altendorf-Hofmann A., Charnley R.M., Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994, 343:1405-1410.
45. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., Fong Y., Kornprat P., Gonen M., Kemeny N., Brennan M.F., Blumgart L.H., D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25:4575-4580.
46. Van Cutsem E., Dicato M., Arber N., Berlin J., Cervantes A., Ciardiello F., De Gramont A., Diaz-Rubio E., Ducreux M., Geva R., Glimelius B., Glynne Jones R., Grothey A., Gruenberger T., Haller D., Haustermans K., Labianca R., Lenz H.J., Minsky B., Nordlinger B., Ohtsu A., Pavlidis N., Rougier P., Schmiegel W., Van de Velde C., Schmoll H.J., Sobrero A., Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: Expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010, 21(Suppl. 6):vi1-10.
47. Vincent F., Bonnin P., Clemessy M., Contreres J.O., Lamande N., Gasc J.M., Vilar J., Hainaud P., Tobelem G., Corvol P., Dupuy E. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009, 69:2853-2860.
48. Wicherts D.A., de Haas R.J., Sebagh M., Saenz Corrales E., Gorden D.L., Levi F., Paule B., Azoulay D., Castaing D., Adam R. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 2011, 98:399-407.
49. Wicherts D.A., Miller R., de Haas R.J., Bitsakou G., Vibert E., Veilhan L.A., Azoulay D., Bismuth H., Castaing D., Adam R. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008, 248:994-1005.
50. Yarmenitis S.D., Kalogeropoulou C.P., Hatjikondi O., Ravazoula P., Petsas T., Siamblis D., Kalfarentzos F. An experimental approach of the Doppler perfusion index of the liver in detecting occult hepatic metastases: Histological findings related to the hemodynamic measurements in Wistar rats. Eur Radiol 2000, 10:417-424.
51. Zorzi D., Chun Y.S., Madoff D.C., Abdalla E.K., Vauthey J.N. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008, 15:2765-2772.